Core Points - A class action securities lawsuit has been filed against KBR, Inc. for alleged securities fraud affecting investors between May 6, 2025, and June 19, 2025 [1][2] - The lawsuit claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global contract [2] - Investors affected by the alleged fraud have until November 18, 2025, to request to be appointed as lead plaintiff in the case [3] Case Details - The complaint alleges that KBR, Inc. misrepresented the status of its partnership with HomeSafe, claiming there were no issues when, in fact, there were material concerns from the U.S. Department of Defense [2] - The statements made by KBR, Inc. regarding its business operations and future prospects were deemed materially false and misleading [2] Next Steps - Affected investors can participate in the lawsuit without incurring any out-of-pocket costs or fees [3] - There is no obligation for investors to serve as lead plaintiffs to share in any potential recovery [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. - The complaint alleges that LifeMD did not disclose rising customer acquisition costs related to its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. Group 2: Company Background - LifeMD, headquartered in New York, provides virtual medical services and prescription delivery [2]. - Berger Montague, the law firm representing the plaintiffs, has a long history in securities class action litigation, having served investors for over five decades [5].

Core Viewpoint - CarMax, Inc. is under investigation for potential violations of federal securities laws, following a significant decline in sales and earnings attributed to a temporary demand boost from U.S. tariffs on cars [1][2][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into CarMax for possible securities law violations [1]. - The investigation is prompted by discrepancies between CarMax's claims of strong demand and the reality of declining sales figures [2]. Group 2: Financial Performance - In fiscal Q2 2025, CarMax reported a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [3]. - The company's net earnings for Q2 were approximately $95.4 million, down from $132.8 million in the previous year, indicating a significant drop in profitability [3]. - Following the earnings report, CarMax's stock price fell by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [3].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that it struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor's Findings - Grant Thornton identified unresolved issues regarding segment reporting and internal controls, which contradicted Simulations Plus's statements about its financial reporting [5].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The case is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - On July 23, 2025, Molina adjusted its full-year 2025 earnings expectation to no less than $19.00 per diluted share, citing a challenging medical cost trend environment [4]. - Following this announcement, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].

Core Viewpoint - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the impact of the Affordable Connectivity Program's termination on the company's customer base and earnings [1][2]. Company Overview - Charter Communications is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program (ACP), which provided funding to subsidize high-speed internet plans for low-income households [3]. Legal Context - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Charter securities, with the case pending in the U.S. District Court for the Southern District of New York [2]. Impact of ACP Termination - The ACP ended in June 2024 due to a lack of federal funding, leading to customer declines at Charter. The company had previously communicated to investors that it was managing the risks associated with the end of the ACP, claiming that the impact was behind them [3][4]. Financial Performance - In the second quarter of 2025, Charter reported a decrease of 117,000 total internet customers, with approximately 50,000 disconnects attributed to the end of the ACP, nearly double the disconnects from the previous quarter. Following this announcement, Charter's stock price fell by $70.25 per share, or 18.4%, from $380.00 to $309.75 [5].

Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, following disappointing financial results and claims of overstated demand for its Prestige fragrances [1][2][3]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products [2]. - Prestige fragrances represent 60% of Coty's total revenues, highlighting the significance of this segment to the company's financial health [2]. Group 2: Financial Performance - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as weaknesses in U.S. execution, retailer inventory buildup, and challenges from previous fiscal year innovations [3]. - The company's stock price fell by $1.05, a decline of over 21%, from $4.86 to $3.81 per share following the announcement of these results [3]. Group 3: Market Dynamics - Coty indicated that there was a slowdown in cosmetics sales due to value-seeking consumer behavior, fatigue with innovation, and specific U.S. factors such as in-store theft measures and immigration policy changes [3].

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from July 29, 2024, to January 6, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - It is alleged that Cepton's Board of Directors failed to adequately explore the third-party offer and did not disclose its terms when recommending the Koito Acquisition to shareholders [5]. - As a result of these actions, shareholders were deprived of the opportunity to meaningfully consider the acquisition, leading to materially false and misleading public statements by the defendants [5]. Group 2: Participation Information - Investors who purchased or sold Cepton, Inc. common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Core Viewpoint - Fortinet, Inc. is facing a class action lawsuit due to alleged securities fraud related to misleading statements about its business performance and the sustainability of its firewall upgrade cycle, which led to significant stock price declines following disappointing financial results [2][3]. Financial Performance - On August 6, 2025, Fortinet reported its Q2 2025 financial results, indicating that it was only "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" [2]. - The company provided weaker than expected revenue guidance for Q3 2025, projecting revenue between $1.67 billion and $1.73 billion [2]. - Following this announcement, Fortinet's share price dropped by $21.28, or approximately 22%, from $96.58 to $75.30 [2]. Lawsuit Details - The lawsuit is on behalf of investors who purchased Fortinet securities from November 8, 2024, to August 6, 2025, alleging that the company made materially false and misleading statements regarding the impact of a "record" round of FortiGate unit upgrades [3]. - Defendants claimed that the upgrade cycle would generate "around $400 million to $450 million in product revenue" in 2025 and 2026, and that it would gain momentum in the second half of 2025 [3]. - The lawsuit contends that the actual refresh cycle was not as lucrative as represented, consisting of old products that were a "small percentage" of the company's business, and that Fortinet misrepresented the true number of upgradable FortiGate firewalls [3].

Core Viewpoint - A class action lawsuit has been filed against Marex Group PLC, alleging significant accounting irregularities and misleading disclosures that have impacted investors during the specified Class Period from May 16, 2024, to August 5, 2025 [1][5]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. - Investors have a 60-day window from the notice date to move the Court to serve as lead plaintiff in this action [2][6]. Allegations Against Marex - A report by NINGI Research on August 5, 2025, accused Marex of engaging in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to conceal losses and inflate profits [3]. - Specific allegations include a $17 million receivable created without basis, a subsidiary's profit inflated by 150%, and a $14.9 million asset sold for only $2.5 million shortly after, with no loss reported [3]. - The report also claimed Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, misclassifying structured note issuance as income [3]. Market Reaction - Following the allegations, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, with unusually high trading volume [4]. Misleading Statements - The complaint alleges that Marex made materially false and misleading statements throughout the Class Period, failing to disclose critical adverse facts about its business and financial health [5]. - Specific failures included undisclosed over-the-counter financial instruments sold to itself and inconsistencies in financial statements among subsidiaries [5].